Dr. Rohit Loomba is an Associate Professor of Medicine in
the Division of Gastroenterology, and Associate Adjunct Professor in the
Division of Epidemiology at University of California at San Diego. He is a leading
expert in translational research and innovative clinical trial design in
nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).
Dr. Loomba is the founding director of the UCSD NAFLD
Translational Research Unit where his team is conducting cutting edge research
in all aspects of NAFLD including non-invasive biomarkers, genetics,
epidemiology, clinical trial design, imaging end-points, and integrated OMICs
using microbiome, metabolome and lipidome. This integrated approach has led to
several innovative applications such as establishment of MRI-PDFF as a
non-invasive biomarker of treatment response in early phase trials in NASH, and
first prospective study of MRE in patients with biopsy-proven NAFLD, and MOZART
Trial being the first trial in NASH with comprehensive MRI and 2D and 3D MRE
assessment paired with liver biopsies in NASH. He follows one of the largest
cohort of well-characterized patients with NAFLD and applies evidence-based
medicine to answer clinically relevant questions to improve management of
patients with chronic liver disease.
He is the founder and principal investigator of the San
Diego Integrated NAFLD Research Consortium (SINC). His research is funded by
the National Institutes of Health, American Gastroenterology Association,
National Science Foundation as well as several investigator initiated research
projects funded by the industry. He is the Principal Investigator for adult
hepatology for the NIDDK-sponsored NASH Clinical Research
Network (2009-19) and is a member of the American Association for the
Study of Liver Diseases.
Dr. Loomba is an elected member of the board of directors of
the American Liver Foundation. He serves as the co-chair of the Research Award
Panel for the American Liver Foundation. In addition, he serves on various
committees of the American Association for the Study of Liver Diseases (AASLD).
He is also an elected member of the steering committee of the Steatosis and
Steatohepatitis Special Interest Group of the AASLD. He serves on the editorial
board of several leading journals, and is the Associate Editor for Alimentary
Pharmacology and Therapeutics, a leading journal in the field of
The types of research conducted includes patient-oriented
clinical research based upon patients seen in the liver clinic, clinical
trials, population-based cohort studies, twin studies, and clinical decision
making by utilizing meta-analytic approaches. He continues to work in close
collaboration with his colleagues at the National Institutes of Health, where
he received his clinical and research training in advanced hepatology.
He leads a multidisciplinary team of trainees, nurses,
clinicians and scientists in conducting cutting edge translational research in
liver disease. Dr. Loomba and his collaborators are leading a major effort into
non-invasive biomarkers especially imaging modalities for assessment of
fat, inflammation, cell injury and fibrosis in patients with chronic liver
diseases, and developing therapies for the treatment of NASH and NASH related
central goal of his research program is to reverse NASH and fibrosis, and stop
progression of liver disease in patients with NAFLD.
Read full bio